069620.KS
069620.KS
KR7069620003
DAEWOONG PHARM
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 70/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±41.9% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.0x).

Beta (Market Relation)
0x
Defensive
Volatility (5Y p.a.)
41.9% p.a.
5-Year Horizon
Max Drawdown (5Y)
-52.3%
5-Year Horizon
Sharpe Ratio
-0.16
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -18.3%
3 Years 43.0% -45.3% -0.11 -1.7%
5 Years 41.9% -52.3% -0.16 -4.3%
10 Years 49.3% -70.8% 0.02 +3.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (41.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -70.8% in the extended horizon.
ende